Clinical Trial Update: Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating the study of weekly Genexol-PM plus gemcitabine in patients with recurrent or metastatic pancreatic adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Pancreas

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Genexol-PM (paclitaxel)

Snippet

Sponsor: Samyang Biopharmaceuticals Corporation | Conditions: Recurrent Adenocarcinoma of the Pancreas, Metastatic Adenocarcinoma of the Pancreas | Phase 2 | Status: UNKNOWN